A novel systemic inflammation response index (SIRI) for predicting the survival of patients with pancreatic cancer after chemotherapy

Clinical implications of systemic inflammatory response markers as independent prognostic factors for advanced pancreatic cancer

(2015) Q. Qi et al.   PANCREATOLOGY

Preoperative platelet to lymphocyte ratio predicts outcome of patients with pancreatic ductal adenocarcinoma after pancreatic resection

(2015) Yoshihiro Shirai et al.   SURGERY

Prognostic significance of pre-operative C-reactive protein and the neutrophil–lymphocyte ratio in resectable pancreatic cancer: a systematic review

(2015) Lewis Stevens et al.   HPB

Prognostic role of the neutrophil-to-lymphocyte ratio in pancreatic cancer: a meta-analysis

(2015) Hao Cheng et al.   Scientific Reports

Cancer statistics, 2014

(2014) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

A Positive Feedback Loop between Mesenchymal-like Cancer Cells and Macrophages Is Essential to Breast Cancer Metastasis

(2014) Shicheng Su et al.   CANCER CELL

Cancer-related inflammation and treatment effectiveness

(2014) Connie I Diakos et al.   LANCET ONCOLOGY

Chronic Pancreatitis and Systemic Inflammatory Response Syndrome Prevent Impact of Chemotherapy with Gemcitabine in a Genetically Engineered Mouse Model of Pancreatic Cancer

(2014) Richard F. Knoop et al.   NEOPLASIA

Elevated preoperative neutrophil/lymphocyte ratio is associated with poor prognosis in soft-tissue sarcoma patients

(2013) J Szkandera et al.   BRITISH JOURNAL OF CANCER

Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer

(2013) M Stotz et al.   BRITISH JOURNAL OF CANCER

Validation of the prognostic relevance of plasma C-reactive protein levels in soft-tissue sarcoma patients

(2013) J Szkandera et al.   BRITISH JOURNAL OF CANCER

The lymphocyte/monocyte ratio predicts poor clinical outcome and improves the predictive accuracy in patients with soft tissue sarcomas

(2013) Joanna Szkandera et al.   INTERNATIONAL JOURNAL OF CANCER

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

(2013) Daniel D. Von Hoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Macrophages mediate gemcitabine resistance of pancreatic adenocarcinoma by upregulating cytidine deaminase

(2013) N Weizman et al.   ONCOGENE

Prospective randomised evaluation of traditional Chinese medicine combined with chemotherapy: a randomised phase II study of wild toad extract plus gemcitabine in patients with advanced pancreatic adenocarcinomas

(2012) Z Meng et al.   BRITISH JOURNAL OF CANCER

The serum miR-21 level serves as a predictor for the chemosensitivity of advanced pancreatic cancer, and miR-21 expression confers chemoresistance by targeting FasL

(2012) Peng Wang et al.   Molecular Oncology

CCL18 from Tumor-Associated Macrophages Promotes Breast Cancer Metastasis via PITPNM3

(2011) Jingqi Chen et al.   CANCER CELL

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

(2011) Thierry Conroy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inflammation and oncogenesis: a vicious connection

(2009) Sergei I Grivennikov et al.   CURRENT OPINION IN GENETICS & DEVELOPMENT

Cytokines as a key component of cancer-related inflammation

(2008) Giovanni Germano et al.   CYTOKINE

CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial

(2008) Viviane Hess et al.   LANCET ONCOLOGY

Cancer-related inflammation

(2008) Alberto Mantovani et al.   NATURE